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Abstract
Background
With the emergence of biotherapies, accurate diagnosis in early arthritis is needed. At this
time, there is no biological marker of psoriatic arthritis.
Objective
To test whether antinuclear antibodies (ANA) can be used as a diagnostic tool in psoriatic
arthritis (PsA), we evaluated the prevalence of ANA in biologic-naïve PsA patients and in
healthy blood donors.
Methods
232 patients from the Rheumatology department, St Marguerite's Hospital, Marseilles, who
fulfilled the CASPAR criteria for PsA, underwent clinical and laboratory investigations. Anti-
nuclear antibodies (ANA), anti-extractable nuclear antigen antibodies (ENA), rheumatoid
factor (RF), anti-citrullinated protein antibodies (ACPA) were assayed. Ninety-one healthy
blood donors were also tested.
Results
Detection of ANA by indirect immunofluorescence was significantly more frequent in sera
from PsA patients than those from controls at serum dilution of 1:100 (57% compared with
40%, Odds Ratio (OR) 1.98 (1.2-3.4) p<0.02) and 1:160 (52% compared with 24%, OR 3,7
(1.9-7.2) p<0.001). No patients had lupus specific autoantibodies, 15 % had RF (34/232),
and 1.7 % had ACPA (4/232).
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Conclusions
Detection of ANA was more frequent in sera from PsA patients than in those from healthy
controls. This suggests that ANA could be a diagnosis orientation tool in PsA. Nevertheless,
the specificity of these antibodies still remains to be investigated.
Introduction
Psoriatic arthritis is inflammatory arthritis associated with psoriasis, a member of the spondylo-
arthritis family [1]. Its diagnosis is not always obvious and relies on specific criteria, like CAS-
PAR criteria [2–4]. The identification of biological markers of PsA would help its diagnosis.
Anti-citrullinated protein antibodies (ACPA) and antinuclear antibodies (ANA) have been
reported in respectively 5% and 7–77% of patients with PsA [5–14]. Anti-TNFα agents, used
for the treatment of psoriasis and PsA, may contribute to the development of ANA in these
patients [15–24]
In this work, we studied: -1-The prevalence of ANA in 232 patients with PsA and 91 healthy
controls and its evolution under anti-TNFα treatment. -2-The prevalence of anti-ENA, anti-
dsDNA, RF and ACPA at baseline in PsA patients. -3-Whether ANA detection and clinical
phenotype in PsA patients were correlated.
Methods
Patients
We retrospectively analyzed 232 patients followed at the Rheumatology department, St Mar-
guerite's hospital, Marseille.
All consecutive venous blood samples (232 samples) from SpA patients, naïve of biologics
and fulfilling the CASPAR criteria, sent to our university hospital immunology laboratory
between November 2009 and March 2015 for routine detection of ANA were included in our
study. After anti-TNF therapy, ANA were assayed once more in 34 patients.
Patients with any confounding disease, which could be associated with ANA positivity (for
example: rheumatoid arthritis, systemic lupus erythematous, scleroderma, inflammatory bowel
disease, dermatomyositis, auto immune thyroid disease, reactive arthritis) were excluded from
this study.
Clinical assessment
For every patient, we retrospectively collected clinical history including assessment of arthritis,
concomitant illnesses and medications taken. Physical examination included a general medical
examination with emphasis on skin, nails, peripheral and axial joints. The number of tender
and swollen joints was recorded as well as the axial presence of syndesmophytes on X ray.
Controls
Ninety-one healthy controls were recruited from the French National Blood Bank in Marseilles.
Ethics. Patients had routine tests. Serum samples and patient information were retrospec-
tively analyzed. They were anonymized prior to analysis.
Healthy donors were registered at the French Blood Bank (ESF) under the number 20012-
0098-7266. All participants gave written informed consent. Serum samples were anonymized
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prior to analysis. Sample collection and analysis (DC-2008-327) was approved by the « Cellule
Bioéthique, direction générale pour la recherche et l’innovation, Ministère de l’Enseignement
Supérieur et de la Recherche » (Ministry bioethics unit).
Detection of anti nuclear antibodies and their specificity
Antinuclear antibodies (ANA) were detected by indirect immunofluorescence (IFI) on HEp-2
cells (Kallestad HEp-2 Cell Line Substrate, 12 well slides, Bio-Rad Laboratories, Hercules, CA)
at a screening dilution of 1:100 for every patient and control. To be in compliance with the new
recommendations regarding screening dilution, a sub group of patients and controls were fur-
ther tested at a dilution of 1: 160 [25,26]. Since serum samples are only kept in our laboratory
for one year, this analysis could only be done for 63 patients. We also analyzed 91 controls at
this dilution.
Anti-ENA and anti-ds DNA antibodies were detected by commercially-available kits (EliA
dsDNA; Phadia, Uppsala, Sweden; now part of Thermo Fisher Scientific).
RF was detected with the commercially available ELISA kit (ORGENTEC Diagnostika
GmbH, Mainz, Germany).
In 34 patients under TNFα blockers, these tests were performed before and after anti-TNFα
treatment.
Statistical analysis
Comparisons between the 2 groups (PsA patients vs controls), with regards to demographic,
clinical, biological and genetic factors, were carried out using chi-square tests incorporating
Yates' correction for continuity when applicable. To evaluate the diagnostic value of ANA in
psoriatic patients, data on sensitivity, specificity, positive predictive value and negative predic-
tive value of the test were calculated. ROC curves could not be performed as IFI provided only
qualitative data (positive or negative) in controls. R statistical software (R Foundation for Sta-
tistical Computing, Vienna, Austria) was used for data analysis. The statistical significance
level was set at p = 0.05.
Results
Clinical features (Table 1)
The PsA group was comprised of 232 patients, 159 women and 73 men, with a mean age of 46
years old (median: 47 years old, range: 18–70 years old) and the control group was comprised
of 91 healthy blood donors, with a mean age of 43 years old (median: 43 years old, range: 21–
69 years old), sex ratio 1.5. Pure peripheral joint involvement was seen in 30%, pure axial
involvement in 9% and involvement of both in 55% of patients (data unknown for 6%).
Twenty-four percent of patients had at least one dactylitis, 83% had skin or nail psoriasis.
Family history of psoriasis was present in 38.5% of patients. Details available on S1 Table.
Axial radiological features
Non-marginal syndesmophytes on the thoracolumbar spine were detected on the X rays of
10% of patients.
ANA Detection
Prior to any biologics, serum from 132 of 232 (57%) PsA patients and 28 of 70 (40%) healthy
controls was positive for ANA at dilution 1:100 (OR 1.98 (1.2–3.4) p<0.02). Titers ranged
from 1:100 to 1:800 (Table 2). To evaluate the predictive value of ANA at 1:100, we calculated
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sensitivity at 58%, specificity at 64%, positive predictive value at 62% and negative predictive
value at 60%
Prior to any biologics, 33 of 63 (52%) PsA patients and 21 of 91 (23%) healthy controls were
positive for ANA at dilution 1:160 (OR 3.7 (1.9–7.2) p<0.001) (Table 3). To evaluate the pre-
dictive value of ANA at 1:160, we calculated sensitivity at 62%, specificity at 71%, positive pre-
dictive value at 54% and negative predictive value at 77%.
For PsA patients ANA were more frequently detected in women than in men: 62% in
women and 45% in men at 1:100, 57% in women and 47% in men at 1:160.
In 95% of patients, ANA displayed a constant speckled pattern. In 5% of patients, ANA also
had a nucleolar speckled pattern.
Table 1. Clinical, biological, thoracolumbar X ray and genetic characteristics of 232 patients with PsA, serum tested for ANA at 1: 100.
Characteristics Total n = 232 ANA + n = 132 ANA − n = 100 p value
Gender
women 159 (69%) 99 (75%) 60 (60%) p<0.02
men 73 (31%) 33 (25%) 40 (40%) NS
Age at blood sample (average, min-max) 46 (18–70) 46 (18–78) 47 (18–70) NS
Age at onset PsA (average, min-max) 40 (18–65) 41 (16–65) 40 (15–65) NS
Duration of PsA (average, min-max) 5 (0–37) 5 (0–24) 6 (0–37) NS
Psoriasis (personal history) n (%) 194 (83%) 110 (83%) 84 (84%) NS
Arthritis pattern at assessment, n (%)
dactylitis 56 (24%) 28 (21%) 28 (28%) NS
peripheral 71 (30%) 46 (34%) 25 (25%) p<0.2
axial only 21 (9%) 13 (6%) 8 (4%) NS
axial and peripheral 127 (55%) 68 (30%) 60 (26%) NS
unknown 13 (6%) 5 (2%) 8 (3%) NS
Axial syndesmophytes on thoracolumbar X ray 23 (10%) 13 (10%) 10 (10%) NS
Biological features (%)
RF + 34 (15%) 23 (17%) 11 (11%) NS
Anti Ds DNA + 0 0 0 NS
Anti SSA 3 (0.5%) 3 (0.5%) 0 NS
Anti SSB 0 0 0 NS
Anti RNP 0 0 0 NS
Anti CCP + (>50UI/L) 4 (1.7%) 2 (0.5%) 2 (0.5%) NS
HLA-B27 16% 16,80% 15% NS
HLA-DR Shared Epitope 36% 35% 38% NS
HLA-DR7 31% 34% 27% NS
HLA-CW6 29% 31% 26% NS
doi:10.1371/journal.pone.0134218.t001
Table 2. Frequency of ANA in serum from PsA patients and healthy controls at dilutions 1: 100.
Biological feature PsA pos 1: 100 Controls pos 1:100 OR CI at 95% p value
Number tested n = 232 n = 70
Total 132/232 (57%) 28/70 (40%) 2.0 1.2–3.4 p<0.02
Women 99/159 (62%) 15/28 (53%) 1.4 0.6–3.2 NS
Men 33/73 (45%) 12/40 (30%) 1.9 0.8–4.0 NS
doi:10.1371/journal.pone.0134218.t002
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None of the patients developed either clinical symptoms of systemic lupus erythematous or
biological signs (absence of anti-dsDNA, antiSm, anti-SSB or anti-RNP antibodies). Among
232 patients, only 3 patients were positive for anti-SSA/Ro antibodies. Rheumatoid factor was
found in 34 patients and anti-CCP antibodies in 4 patients with titers above 50 IU/mL (normal
<20 IU).
HLA genetic background
The frequencies of HLA-B27, HLA-DR7, HLA-Cw6, the HLA-DRB1 shared epitope were not
significantly different in PsA patients with regards to ANA status.
ANA follow-up under anti-TNF treatment in PsA patients
We followed 34 PsA patients under treatment with anti-TNF. Before treatment, 20 were ANA
negative and 14 were ANA positive.
After a mean of 58 months (median: 32 months) of treatment with anti-TNF, 11/ 20 (55%)
of ANA negative patients became positive. Among the 14 patients who had ANA before anti-
TNF treatment, all remained positive and 5 increased their ANA titer (from 5 first detected at
1:100, 2 became positive at 1:200, 2 at 1:400, and 1 at 1:800)
Discussion
Psoriatic arthritis, a condition defined by the association of psoriasis and inflammatory arthri-
tis, suffers from the lack of any unambiguous diagnostic marker. This is especially important
nowadays as the range of treatments for arthritis has been significantly improved by biologics,
the usage of which is usually restricted to well characterized types of arthritis: rheumatoid
arthritis, ankylosing spondylitis, psoriatic arthritis.
Here, we wondered whether antinuclear antibodies could be of some help in diagnosing
psoriatic arthritis.
We found that, if one sets positivity at a titer of 1:160, more than half of the patients with
psoriatic arthritis and less than a quarter of healthy controls have ANA in their sera.
These findings are not entirely new: indeed, as early as 1966, Sonnischen reported that 77%
of patients with psoriatic arthritis had ANA [27] even if these first results, given at a dilution of
1:40 could not be reproduced. In other series, patients were mostly screened at a dilution of
1:80 [28]. Other groups which have tested for ANA in patients with psoriasis (with or without
arthritis), at a screening dilution of 1:80, reported respectively that 11%, 34%, 9%, 22% of
patients had ANA at baseline [17,20,22–24]
However, our study is the first providing a healthy control group and a patient group tested
at the same time. Previous studies just compared their findings with epidemiologic data
obtained from the general population. The frequency of ANA was higher in women than in
men in both the PsA and the healthy control groups, as previously described [29].
Table 3. Frequency of ANA in serum from PsA patients and healthy controls at dilutions 1: 160.
Biological feature PsA pos 1: 160 Controls pos 1:160 OR CI at 95% p value
Number tested n = 63 n = 91
Total 33/63 (52%) 21/91 (23%) 3.7 1.9–7.2 p<0.001
Women 26/46 (57%) 8/34 (23%) 4.2 1.6–11.2 p<0.01
Men 8/17 (47%) 12/55 (22%) 3.2 1.0–10.0 p<0.05
doi:10.1371/journal.pone.0134218.t003
Antinuclear Antibodies in Patients with Psoriatic Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0134218 July 31, 2015 5 / 8
ANA tended to be associated with peripheral disease even if this feature did not reach
significance.
In 34 patients tested before and after biotherapy, 11/20 (55%) negative sera before anti-TNF
treatment became ANA positive after treatment. This is in accordance with previous studies: in
the University of Toronto’s prospective PsA cohort autoantibodies developed in 8/16 PsA
patients treated with infliximab [15]. In psoriatic patients treated with infliximab (with or with-
out arthritis), the prevalence of ANA always increased: respectively from 11 to 72% [17], from
9 to 48% [30], and from 22 to 63% [22] with a gradual increase both in ANA titer and in per-
centage of ANA pattern even restricted for anti dsDNA and anti nucleosome [20,22]. Interest-
ingly, in the study by Lora et al., patients who developed ANA positivity showed a faster
clinical response to infliximab. Contrary to these findings, Hoffmann et al. showed that higher
pretreatment ANA titers were associated with a loss of response to infliximab and induction of
anti-infliximab antibodies. In our study, we could not find any correlation between ANA posi-
tivity and clinical evolution.
Conclusion
More than half of the patients and less than 25% of healthy controls tested positive for ANA at
a serum dilution of 1:160 in a series of 232 patients with PsA and 91 healthy controls. Further
studies are needed to characterize ANA fine specificity and turn them into a diagnostic tool.
Supporting Information
S1 Table. Clinical and biological data of PsA patients.
(PDF)
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